XYRATEX LTD Form 6-K February 17, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

February 17, 2009 Commission File Number:0001284823

XYRATEX LTD

(Translation of registrant s name into English)

Langstone Road,

Havant

PO9 1SA

United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

FOR IMMEDIATE RELEASE

Xyratex Ltd Announces Final Results for the Fourth Quarter and Fiscal Year 2008

Havant, UK, February 17, 2009 Xyratex Ltd (Nasdaq: XRTX), a leading provider of enterprise class data storage subsystems and storage process technology, today announced final results for the fourth quarter and fiscal year ended November 30, 2008. These results represent an update to the preliminary results announced on January 6, 2009.

The only change from the results announced on January 6 is related to the specific provision representing inventory and future vendor claims. This provision was associated with a specific Networked Storage Solutions customer product forecast which indicated a transition to an updated version sooner than originally planned, giving rise to an exposure on long lead time components. Within its preliminary results the Company provided what it believed would be its maximum probable exposure of \$9.5 million.

Following a thorough assessment of the exposure and mitigation opportunities, it has been concluded that the total provision required is \$2 million and hence the Company has been able to write back \$7.5 million of the preliminary provision.

The updated and final results for Xyratex Ltd for the fourth quarter and fiscal year ended November 30, 2008 are summarized below:

- Revenues for the fourth quarter were \$285.4 million, an increase of 15.1% compared to revenues of \$248 million for the same period last year. Revenues for the full year were \$1,049.7 million, an increase of 12.7%, compared to revenues of \$931.6 million for fiscal year 2007.
- Fourth quarter GAAP net loss was \$55.7 million, or \$1.92 per diluted share compared to GAAP net income of \$11.7 million in the same period last year.
- A GAAP net loss for fiscal year 2008 of \$47.9 million, or \$1.64 per diluted share compared to a GAAP net income of \$28.1 million for fiscal year 2007.
- Fourth quarter non-GAAP net income of \$0.4 million, or \$0.02 per diluted share compared to non-GAAP net income of \$13.1 million in the same quarter a year ago.
- A non-GAAP net income for fiscal year 2008 of \$16.2 million, or a diluted earnings per share of \$0.56 compared to non-GAAP net income of \$37.5 million, or \$1.26 per diluted share, for fiscal year 2007(1).
- Gross profit margin in the fourth quarter of 12.5%, compared to 18.5% in the same period last year and 17.6% in the prior quarter.

These results will be reflected in the Company s Annual Report on Form 20-F to be issued shortly.

(1) Non-GAAP net income (loss) and diluted earnings (loss) per share excludes (a) amortization of intangible assets, (b) equity compensation expense, (c) specified non-recurring or non-cash items, such as the impairment of goodwill and the valuation allowance against a deferred tax asset, and (d) the related tax effects. Reconciliation of non-GAAP net income and diluted earnings per share to GAAP net income and GAAP diluted earnings per share is included in a table immediately following the condensed consolidated statements of cash flow below.

The intention in providing these non-GAAP measures is to provide supplemental information regarding the Company s operational performance whilst recognizing that they have material limitations and that they should only be referred to with reference to the corresponding GAAP measure.

The Company believes that the provision of these non-GAAP financial measures is useful to investors and investment analysts because it enables comparison to the Company's historical operating results, those of competitors and other industry participants and also provides transparency to the measures used by management in operational and financial decision making. In relation to the specific items excluded:

(a) intangible assets represent costs incurred by the acquired business prior to acquisition, are not cash costs and will not be replaced when the assets are fully amortized and therefore the exclusion of these costs provides management and investors with better visibility of the costs required to generate revenue over time; (b) equity compensation expense is non-cash in nature, is outside the control of management during the period in which the expense is incurred and in addition has not been measured consistently as a result of the implementation of FAS 123R; (c) the impairment of goodwill and the valuation allowance against the deferred tax asset is non-recurring, non-cash and is not comparable across periods or with other companies; (d) the exclusion of the related tax effects of excluding items (a) to (c) is necessary to show the effect on net income of the change in tax expense that would have been recorded if these items had not been incurred.

Safe Harbor Statement

This press release contains forward looking statements. These statements relate to future events or our future financial performance. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that might cause such a difference include our inability to compete successfully in the competitive and rapidly changing marketplace in which we operate, failure to retain key employees, changes in our customers volume requirements, cancellation or delay of projects and adverse general economic conditions in the United States and internationally. These risks and other factors include those listed under Risk Factors and elsewhere in our

3

Annual Report on Form 20-F as filed with the Securities and Exchange Commission (File No. 000-50799). In some cases, you can identify forward-looking statements by terminology such as may, will, should, expects, intends, plans, anticipates, believes, estimates, continue, or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

About Xyratex

Xyratex is a leading provider of enterprise class data storage subsystems and storage process technology. The company designs and manufactures enabling technology that provides OEM and disk drive manufacturers with data storage products to support high-performance storage and data communication networks. Xyratex has over 20 years of experience in research and development relating to disk drives, storage systems and high-speed communication protocols.

Founded in 1994 in an MBO from IBM, and with headquarters in the UK, Xyratex has an established global base with R&D and operational facilities in Europe, the United States and South East Asia.

For more information, visit www.xyratex.com.

Contacts:

Xyratex Investor Relations

Brad Driver, +1 408-325-7260

bdriver@us.xyratex.com

www.xyratex.com

4

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended, November 30, November 30,			N	ovember 30,	Ended November 30,				
		2008	2007			2008		2007		
	(US dollars in thousands, except per share amounts)									
Revenues:										
Networked Storage Solutions	\$	222,300	\$	187,216	\$	855,770	\$	693,990		
Storage Infrastructure		63,127		60,772		193,946		237,643		
Total revenues		285,427		247,988		1,049,716		931,633		
Cost of revenues		249,827		202,133		891,139		762,582		
Gross profit:										
Networked Storage Solutions		18,643		28,165		107,275		100,573		
Storage Infrastructure		17,234		18,046		52,566		69,716		
Equity compensation		(277)		(356)		(1,264)		(1,238)		
Total gross profit		35,600		45,855		158,577		169,051		
Operating expenses:										
Research and development		22,726		19,370		85,897		77,559		
Selling, general and administrative		15,984		16,532		63,686		61,977		
Amortization of intangible assets		1,223		2,485		4,882		7,304		
Impairment of goodwill		34,256				34,256				
Total operating expenses		74,189		38,387		188,721		146,840		
Operating income (loss)		(38,589)		7,468		(30,144)		22,211		
Other income								890		
Interest income, net		166		1,030		1,618		3,283		
Income (loss) before income taxes		(38,423)		8,498		(28,526)		26,384		
Provision (benefit) for income taxes		17,324		(3,229)		19,383		(1,725)		
Net income (loss)	\$	(55,747)	\$	11,727	\$	(47,909)	\$	28,109		
Net earnings (loss) per share:										
Basic	\$	(1.92)	\$	0.40	\$	(1.64)	\$	0.97		
Diluted	\$	(1.92)	\$	0.39	\$	(1.64)	\$	0.94		
Weighted average common shares (in thousands), used in										
computing net earnings (loss) per share:										
Basic		29,096		29,100		29,157		28,985		
Diluted		29,096		29,758		29,157		29,866		
		, ,								
		5								

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	November 30, 2008	November 30, 2007			
	(US dollars and amo thousands)				
ASSETS					
Current assets:					
Cash and cash equivalents	\$ 28,013	\$	70,678		
Accounts receivable, net	140,879		122,327		
Inventories	128,183		91,662		
Prepaid expenses	2,746		2,994		
Deferred income taxes	1,000		3,000		
Other current assets	4,430		8,275		
Total current assets	305,251		298,936		
Property, plant and equipment, net	47,229		37,421		
Intangible assets, net	11,162		54,175		
Deferred income taxes	9,545		19,743		
Total assets	\$ 373,187	\$	410,275		
LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities:					
Accounts payable	\$ 111,295	\$	96,046		
Employee compensation and benefits payable	9,745		13,280		
Deferred revenue	8,386		15,212		
Income taxes payable	2,573		1,165		
Other accrued liabilities	27,599		11,311		
Total current liabilities	159,598		137,014		
Long-term debt					
Total liabilities	159,598		137,014		
Shareholders equity					
Common shares of Xyratex Ltd (in thousands), par value \$0.01 per share 70,000					
authorized, 29,146 and 29,117 issued and outstanding	291		291		
Additional paid-in capital	366,067		356,268		
Accumulated other comprehensive income	(13,603)		1,847		
Accumulated deficit	(139,166)		(85,145)		
Total shareholders equity	213,589		273,261		
Total liabilities and shareholders equity	\$ 373,187	\$	410,275		
6					

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended				
	No	vember 30, 2008	November 30, 2007		
	(US dollars in thousands)				
Cash flows from operating activities:		`	,		
Net income (loss)	\$	(47,909)	\$ 28,109		
Adjustments to reconcile net income (loss) to net cash provided by operating					
activities:					
Depreciation		15,770	13,683		
Amortization of intangible assets		4,882	7,304		
Impairment of intangible assets		34,256			
Non-cash equity compensation		7,646	8,057		
Loss on sale of assets		185	341		
Changes in assets and liabilities, net of impact of acquisitions and divestitures					
Accounts receivable		(18,552)	(17,003)		
Inventories		(36,521)	1,449		
Prepaid expenses and other current assets		1,455	(2,956)		
Accounts payable		15,249	11,150		
Employee compensation and benefits payable		(3,535)	(3,365)		
Deferred revenue		(6,826)	(1,091)		
Income taxes payable		1,408	(476)		
Deferred income taxes		16,944	(1,616)		
Other accrued liabilities		2,718	(2,266)		
Net cash provided by (used in) operating activities		(12,830)	41,320		
Cash flows from investing activities:					
Investments in property, plant and equipment		(25,763)	(16,974)		
Acquisition of intangible assets			(4,833)		
Acquisition of business, net of cash received			(1,661)		
Net cash used in investing activities		(25,763)	(23,468)		
Cash flows from financing activities:					
Payments of short-term borrowings			(7,000)		
Repurchases of common shares		(6,116)			
Proceeds from issuance of shares		2,044	2,905		
Net cash used in financing activities		(4,072)	(4,095)		
Change in cash and cash equivalents		(42,665)	13,757		
Cash and cash equivalents at beginning of period		70,678	56,921		
Cash and cash equivalents at end of period	\$	28,013	\$ 70,678		

XYRATEX LTD

SUPPLEMENTAL INFORMATION

	Three Months Ended November 30, November 30, 2008 2007 (US dollars in thousands, except per share amounts)			mber 30, 2007 ds, except	Year E November 30, 2008 (US dollars in the per share a			November 30, 2007 nousands, except	
Summary Reconciliation Of GAAP Net Income To Non-GAAP Net Income									
GAAP net income (loss)	\$	(55,747)	\$	11,727	\$	(47,909)	\$	28,109	
Amortization of intangible assets		1,223		2,485		4,882		7,304	
Impairment of goodwill		34,256				34,256			
Equity compensation		1,755		2,237		7,646		8,057	
Other income								(890)	
Tax effect of impairment of goodwill		(9,592)				(9,592)			
Tax effect of other non-GAAP adjustments		(1,024)		(1,602)		(3,791)		(4,050)	
Valuation allowance against UK deferred tax asset		29,466				29,466			
Effect on deferred tax of changes to UK tax rates and exchange rates		110		(1,743)		1,254		(1,040)	
Non-GAAP net income	\$	447	\$	13,104	\$	16,212	\$	37,490	
Summary Reconciliation Of Diluted GAAP Earnings Per Share To Diluted Non-GAAP Earnings Per Share									
Diluted GAAP earnings (loss) per share	\$	(1.92)	\$	0.39	\$	(1.64)	\$	0.94	
Amortization of intangible assets		0.04		0.08		0.17		0.24	
Impairment of goodwill		1.18		0.00		1.17		0.24	
Equity compensation		0.06		0.08		0.26		0.27	
Other income		0.00		0.00		0.20		(0.03)	
Tax effect of impairment of goodwill		(0.33)				(0.33)		(0.03)	
Tax effect of other non-GAAP adjustments		(0.03)		(0.05)		(0.13)		(0.14)	
Valuation allowance against UK deferred tax asset		1.01		(0.03)		1.01		(0.11)	
Effect on deferred tax of changes to UK tax rates and exchange rates		1.01		(0.06)		0.04		(0.03)	
Diluted non-GAAP earnings per share	\$	0.02	\$	0.44	\$	0.56	\$	1.26	
Summary Of Equity Compensation									
Cost of revenues		277		356		1,264		1,238	
Research and development		567		711		2,469		2,477	
Selling, general and administrative		911		1,170		3,913		4,342	
Total equity compensation		1,755		2,237		7,646		8,057	

Edgar Filing: XYRATEX LTD - Form 6-K SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

XYRATEX LTD (Registrant)

Date: February 17, 2009 By: /s/ Richard Pearce

Name: Richard Pearce Title: Chief Financial Officer

9